Information Provided By:
Fly News Breaks for March 9, 2015
AVEO
Mar 9, 2015 | 06:46 EDT
RBC Capital upgraded Aveo Pharmaceuticals to Sector Perform from Underperform and increased its price target to $3 from 2. Since the tivozanib in renal cancer, The firm said Aveo has made progress in restructuring, outlining its biomarker strategy, showing an ability to partner with the OPHT deal, and and could file for a tivozanib review in the EU.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.